The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
A phase 3 randomized, placebo‐controlled, double‐blind, clinical trial of the effect of modafinil on cancer‐related fatigue among 631 patients receiving chemotherapy: A University of Rochester Cancer Center Community Clinical Oncology Program Research base study
Open accessAbstract
BACKGROUND: Cancer‐related fatigue is a debilitating symptom affecting psychosocial functioning and quality of life in 70% to 100% of cancer patients during and after treatment. The authors examined the effect of 200 mg of modafinil daily on the severity of cancer‐related fatigue. METHODS: The authors conducted a multicenter, randomized, double‐blind, placebo‐controlled, phase 3, clinical trial to examine the effect of modafinil on patient‐reported fatigue in cancer patients undergoing chemotherapy. A sample of 877 cancer patients beginning chemotherapy at 23 geographically separate University of Rochester Cancer Center (URCC) Community Clinical Oncology Program (CCOP) affiliates were assessed for fatigue. Patients who reported fatigue (N = 867) were randomly assigned to receive either 200 mg of oral modafinil (Provigil) daily or a placebo. Treatment began on Day 5 of Cycle 2 and ended after Day 7 of Cycle 4. Fatigue and depression were assessed during Cycles 2 to 4 by using psychometrically valid measures. Group differences (treatment vs control) in the worst level of fatigue during the previous week at Cycle 4 were examined by using an analysis of covariance (ANCOVA) adjusting for baseline fatigue (Cycle 2). RESULTS: There were 631 patients (315 modafinil, 316 placebo) who provided evaluable data. ANCOVA showed a significant interaction between treatment condition and baseline fatigue (P = .017), where patients with severe baseline fatigue (n = 458) benefited from modafinil, whereas patients with mild or moderate fatigue did not. Modafinil had no statistically significant effect on depression (P > .05). CONCLUSIONS: Modafinil may be useful in controlling cancer‐related fatigue in patients who present with severe fatigue but is not useful in patients with mild or moderate fatigue. Cancer 2010. © 2010 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale
Johns, M. W. (1991) · Sleep · doi:10.1093/sleep/14.6.540 · Cited by 17,364
RUBIN, D. B. (1976) · Biometrika · doi:10.1093/biomet/63.3.581 · Cited by 9,925
Kangas, M., Bovbjerg, D. H., & Montgomery, G. H. (2008) · Psychological Bulletin · doi:10.1037/a0012825 · Cited by 428
Morrow, G. R., Hickok, J. T., Roscoe, J. A., Raubertas, R. F., Andrews, P. L. R., Flynn, P. J., Hynes, H. E., Banerjee, T. K., Kirshner, J. J., & King, D. K. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.070 · Cited by 324 · cited 1×
“Our previous research showed that paroxetine hydrochloride (Paxil) alleviated depression but had no significant effect on cancer-related fatigue.(27,21) Table 4.”
BackgroundSelf-citation
Cited by
Cancer-related fatigue—mechanisms, risk factors, and treatments
Bower, J. E. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.127 · Cited by 1,666
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Cancer-Related Fatigue, Version 2.2015
Berger, A. M., Mooney, K., Alvarez-Perez, A., Breitbart, W. S., Carpenter, K. M., Cella, D., Cleeland, C., Dotan, E., Eisenberger, M. A., Escalante, C. P., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0122 · Cited by 949
Bower, J. E., Bak, K., Berger, A., Breitbart, W., Escalante, C. P., Ganz, P. A., Schnipper, H. H., Lacchetti, C., Ligibel, J. A., Lyman, G. H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.4495 · Cited by 671
Temel, J. S., Abernethy, A. P., Currow, D. C., Friend, J., Duus, E. M., Yan, Y., & Fearon, K. C. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00558-6 · Cited by 639
Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment
Fabi, A., Bhargava, R., Fatigoni, S., Guglielmo, M., Horneber, M., Roila, F., Weis, J., Jordan, K., & Ripamonti, C. I. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.016 · Cited by 570
Wang, X. S., Zhao, F., Fisch, M. J., O'Mara, A. M., Cella, D., Mendoza, T. R., & Cleeland, C. S. (2014) · Cancer · doi:10.1002/cncr.28434 · Cited by 369
Henson, L. A., Maddocks, M., Evans, C., Davidson, M., Hicks, S., & Higginson, I. J. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00470 · Cited by 367
Troublesome Symptoms in Cancer Survivors: Fatigue, Insomnia, Neuropathy, and Pain
Pachman, D. R., Barton, D. L., Swetz, K. M., & Loprinzi, C. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.7238 · Cited by 282
Bower, J. E., Lacchetti, C., Alici, Y., Barton, D. L., Bruner, D., Canin, B. E., Escalante, C. P., Ganz, P. A., Garland, S. N., Gupta, S., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00541 · Cited by 275
Self-citationThe Growth of Palliative Care in the United States
Hughes, M. T., & Smith, T. J. (2014) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-032013-182406 · Cited by 257
Katakami, N., Uchino, J., Yokoyama, T., Naito, T., Kondo, M., Yamada, K., Kitajima, H., Yoshimori, K., Sato, K., Saito, H., et al. (2018) · Cancer · doi:10.1002/cncr.31128 · Cited by 239
Evidence‐based treatment of depression in patients with cancer
Li, M., Fitzgerald, P., & Rodin, G. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.7372 · Cited by 236
Pharmacological treatments for fatigue associated with palliative care
Mücke, M., Mochamat, M., Cuhls, H., Peuckmann-Post, V., Minton, O., Stone, P., & Radbruch, L. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006788.pub3 · Cited by 227
Neurobiological studies of fatigue
Harrington, M. E. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.07.004 · Cited by 112
“Modafinil was shown to be effective in treating patients with severe cancer-related fatigue (Jean-Pierre et al., 2010), and HIV-related fatigue (Rabkin et al., 2011) but was not effective for fatigue associated with multiple sclerosis (Kos et al., 2008).”
An Overview of the Clinical Uses, Pharmacology, and Safety of Modafinil
Murillo-Rodríguez, E., Barciela Veras, A., Barbosa Rocha, N., Budde, H., & Machado, S. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00374 · Cited by 91
Pharmacologic Interventions for Fatigue in Cancer and Transplantation: A Meta-Analysis
Tomlinson, D., Robinson, P. D., Oberoi, S., Cataudella, D., Culos-Reed, N., Davis, H., Duong, N., Gibson, F., Götte, M., Hinds, P., et al. (2018) · Current Oncology · doi:10.3747/co.25.3883 · Cited by 68
A Practical Approach to Fatigue Management in Colorectal Cancer
Aapro, M., Scotte, F., Bouillet, T., Currow, D., & Vigano, A. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.04.010 · Cited by 54
Cancer-related fatigue: impact on patient quality of life and management approaches
Yeo, T. P., & Cannaday, S. (2015) · Nursing: Research and Reviews · doi:10.2147/nrr.s41957 · Cited by 21
Evaluation and management of fatigue in oncology: A multidimensional approach
Tazi, E. M., & Errihani, H. (2011) · Indian Journal of Palliative Care · doi:10.4103/0973-1075.84528 · Cited by 10
Psychiatric Issues in Cancer Patients
Roth, A. J., & Jaeger, A. (2018) · The American Cancer Society's Principles of Oncology · doi:10.1002/9781119468868.ch29 · Cited by 2
Metadata
- Authors
- Jean‐Pierre, P., Morrow, G. R., Roscoe, J. A., Heckler, C., Mohile, S., Janelsins, M., Peppone, L., Hemstad, A., Esparaz, B. T., & Hopkins, J. O.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2010-04-27
- Volume
- 116
- Issue
- 14
- Pages
- 3513-3520
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1509242347
- Cited by
- 191
- References
- 4
- FWCI
- 7.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.